Biologics manufacturers in the USA must now submit draft labeling in structured product labeling (SPL) format to the Food and Drug Administration's Center for Biologics Evaluation and Research as part of a Biologic License Application, supplemental BLA or prior approval supplement.
The SPL mandate, which requires an XML-based, Health Level 7 standard, is the result of the FDA's e-labeling rule issued December 11, 2003, and the subsequent April 2005 guidance, "Providing Regulatory Submissions in Electronic Format - Content of Labeling." Analogous requirements have applied to drugs since October 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze